The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
<p>Abstract</p> <p>Background</p> <p>Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies. The HSP90 family includes the cytosolic HSP90 (HSP90AA1), the ER paralogue gp96 (HSP90B1) and...
Main Authors: | Li Zihai, Chiosis Gabriela, Bona Robert D, Usmani Saad Z |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-10-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://www.jhoonline.org/content/3/1/40 |
Similar Items
-
A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90).
by: Dea Shahinas, et al.
Published: (2013-01-01) -
Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes
by: Tony Taldone, et al.
Published: (2013-03-01) -
The universe of Hsp90
by: Stankiewicz Marta, et al.
Published: (2012-02-01) -
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
by: Toshiki Kijima, et al.
Published: (2018-05-01) -
Molecular characterization of the Hsp70/Hsp90 organizing protein (Hop) phosphorylation, subcellular localization and interaction with Hsp90
by: Daniel, Sheril
Published: (2008)